iPSC-derived midbrain dopaminergic neurons The main pathological feature of Parkinson’s disease (PD) is the progressive degeneration and death of dopaminergic (DA) neurons in the substantia nigra of the brain. Therefore, cell replacement therapy is expected to become the third-generation therapy for PD following drug and surgical treatment. Sufficient and healthy DA neurons were differentiated from iPSC, and then were transplanted into the striatum to replace the missing DA neurons, so as to rebuild the physiological DA system in vivo to cure PD.
Progress of research and development Nuwacell Biotechnologies Co., Ltd. can produce midbrain DA neurons from iPSC on a large scale, and has completed the research on pharmaceutical technology, and is carrying out non-human primate Parkinson’s animal model experiments. In the future, Nuwacell Biotechnologies Co., Ltd. will be able to provide two different types of dopaminergic precursor neurons from autologous sources and from super donor banks to meet different therapeutic needs.
Midbrain DA neurons are currently the most promising treatment for overcoming Parkinson's disease. We are acceleratig the process and striving for early approval to bring new hope to the majority of Parkinson patients.
